By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Dynavax Technologies Corporation 

2929 Seventh Street
Suite 100
Berkeley  California   94710  U.S.A.
Phone: 510-848-5100 Fax: 510-848-1379


Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. We develop cutting edge immunotherapies based on Toll-Like Receptor (TLR) biology and its ability to modulate the immune system.

HEPLISAV-B™ - Our Lead Product Candidate

HEPLISAV-B is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response providing improved protection against hepatitis B. The ongoing Phase 3 study is designed to provide a sufficiently-sized safety database for the FDA to complete its review of Dynavax's biologics license application.

SD-101 - Cancer Immunotherapy

We are utilizing our expertise in TLR biology to develop treatments for cancer by focusing the power of the body’s immune response on cancer cells through optimal stimulation of TLR9 signaling. Our lead cancer immunotherapy product candidate, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells (PDC) to antigen-presenting cells. Our approach provides multiple mechanisms for attacking the tumors along with developing immune memory associated with antigens found in the tumor.

Immune-Mediated Diseases

TLR signaling plays an important role in a variety of immune-mediated diseases including asthma and certain autoimmune and inflammatory diseases. Through modulation of TLR signaling we are developing product candidates that can inhibit stimulation of TLRs that lead to autoimmune and inflammatory diseases as well using TLR agonist to rebalance the Th1 versus Th2 response in asthma

Key Statistics

Ownership: Public

Web Site: Dynavax
Symbol: DVAX

Company News
Dynavax (DVAX) Announces FDA Advisory Committee Meeting To Review HEPLISAV-B 4/3/2017 11:02:59 AM
Dynavax (DVAX) Announces Upcoming Data Presentations For Three TLR9 Agonist Programs At The 2017 AACR Annual Meeting 3/20/2017 8:34:12 AM
Dynavax (DVAX) Reports Fourth Quarter And Year End 2016 Financial Results And Company Update 3/13/2017 7:21:21 AM
Bay Area’s Dynavax (DVAX) Shifts Focus to Immune-Oncology, Cuts 40% of Staff 3/13/2017 5:59:39 AM
Dynavax (DVAX) Presents Promising Clinical Data From Lead Immuno-Oncology Candidate, SD-101, At The International Congress On Targeted Anticancer Therapies 3/6/2017 10:02:34 AM
Dynavax (DVAX) To Present At Cowen and Company 37th Annual Health Care Conference 3/2/2017 7:46:26 AM
Dynavax (DVAX) Announces FDA Acceptance For Review Of Its Complete Response To November 2016 CRL And PDUFA Action Date For HEPLISAV-B 3/1/2017 9:45:37 AM
Dynavax (DVAX) To Present At The 2017 RBC Capital Markets Global Healthcare Conference 2/16/2017 8:11:03 AM
Dynavax (DVAX) In 2017: Hero Or Zero? 1/19/2017 5:51:41 AM
Dynavax (DVAX) To Present At J.P. Morgan 35th Annual Healthcare Conference 1/9/2017 11:19:43 AM